Colorectal NeoplasmsColorectal Neoplasms MalignantColorectal Neoplasms, Hereditary NonpolyposisHereditary Nonpolyposis Colon Cancer
Investigational drug(s) / intervention(s)
Blood Product
Blood Product: An (extra) blood test will be done on participants. This will be analyzed for circulating tumor DNA (ctDNA) via a multi-omics approach.
Study summary
The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages.
Participants will be asked to take an extra blood test, which will be analyzed further in the lab.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
(suspect) Lynch Syndrome carriers who:
* Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor;
* Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet;
* Have granted informed consent to participate in this study.
Exclusion Criteria:
(suspect) Lynch Syndrome carriers who:
* Are unwilling to undergo extra blood sampling;
* Are under the age of 18;
* Have no newly diagnosed tumors at time of inclusion;
* Have been treated for their tumor at time of inclusion;
* Are not able to read or understand Dutch language or are mentally not capable.
Primary outcome measure(s)
Estimated ctDNA fractions in blood — Measurement at baseline ctDNA presence will be measured against a (presently not specified) threshold, creating a divide between 'detectable' and 'non-detectable'.
Tumor pathology — Measurement at baseline Tumor pathology will be revised to later compare with estimated ctDNA presence.
Trial sites (2)
Facility
City
Region
Status
Leiden University Medical Center
Leiden
South Holland
Not Yet Recruiting
Erasmus MC
Rotterdam
South Holland
Recruiting
More Erasmus Medical Center trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
